EHHADH

Across TCGA pan-cancer cohorts, EHHADH mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated EHHADH data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher EHHADH mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated EHHADH expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

CCRCC, GBM, and LSCC are the cancer types where EHHADH mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	1.000	0.729	.017	31	view →
GBM	OS	Tertile	All	0.325	0.744	<.001	26	view →
LSCC	DFS	Quartile	All	0.919	1.000	.006	18	view →
PDAC	DFS	Median	II,III,IV	0.601	0.840	.017	9	view →
OV	DFS	Tertile	All	0.644	1.000	.045	4	view →
HNSC	DFS	Median	IV	0.562	0.762	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

EHHADH–CCRCC (DFS)

Open the CCRCC breakdown →